Emapticap pegol

N/A

Report date: 2022/07/19 20:00:45
NME

Base Information

Drug NameEmapticap pegol
Drug Alias Name培艾马替卡emapticap pegol培戈-依玛替卡emapticapum pegolumNOX-E36 +[6] 
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide
Mechanisms of ActionC-C motif chemokine 2 inhibitors
TargetsC-C motif chemokine 2
Therapy Area/IndicationsDiabetes Mellitus, Type 2Lupus Erythematosus, SystemicAlbuminuria +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaPolandRomania +[6] 
CombinationsNo
Global Highest StatusPending (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesNoxxon Pharma Ag
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesTme Pharma AGSingapore Eye Research Institute
Active IndicationsN/A
Inactive IndicationsDiabetes Mellitus, Type 2Lupus Erythematosus, SystemicAlbuminuria +[5] 

Other Information

ATC CodeN/A
Related LinksN/A